WASHINGTON, April 29 (Reuters) - Dendreon Corp DNDN.O won U.S. approval on Thursday to sell a vaccine to treat men with advanced prostate cancer and the company's shares soared 15 percent.
The Provenge vaccine is the first vaccine to treat any type of cancer. The Food and Drug Administration said in a statement Provenge offered a new option to men with advanced prostate cancer who have limited options. (Reporting by Lisa Richwine, editing by Maureen Bavdek)
Our Standards: The Thomson Reuters Trust Principles.